Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EPAX acquisition?

This article was originally published in The Tan Sheet

Executive Summary

"EPAX AS would be the only significant omega-3 supplier to be fully integrated from fishing to high-quality omega-3 oils" if acquired by Norwegian fishery Austevoll Seafood ASA, according to EPAX CEO Bjorn Refsum. Austevoll Seafood entered into a letter of intent with Ferd Private Equity Fund for acquisition of the investment firm's EPAX shares Dec. 22. "We already see tendencies of crude fish oil supply scarcity," Refsum said. "Through Austevoll Seafood we would be able to expand our secure access to quantity as well as quality - ensuring that our products continue to meet the high standards for which EPAX's oil is known." The fishery also supports EPAX's investment plan "to ensure increased production" at the firm's plant in Aalesund, Norway, Refsum said, adding the plan should be realized in 2007...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel